Juno Therapeutics Inc. (JUNO)

86.96
0.09 0.10
Prev Close 86.87
Open 86.97
Day Low/High 86.90 / 87.01
52 Wk Low/High 19.62 / 87.01
Volume 3.70M
Avg Volume 4.51M
Exchange
Shares Outstanding 116.11M
Market Cap 10.10B
EPS -4.10
Div & Yield N.A. (N.A)

A Steady but Sloppy Day

Awaiting Yellen, but some churn wouldn't hurt.

5 Stocks Ready for Breakouts: Juno Therapeutics, Cheetah Mobile and More

5 Stocks Ready for Breakouts: Juno Therapeutics, Cheetah Mobile and More

These stocks look poised to break out and trade higher from current levels.

Small but Positive Response to Fed

Traders get aggressive with 'junk' biotech.

'Mad Money' Lightning Round: Just Say No to Conoco Stock

'Mad Money' Lightning Round: Just Say No to Conoco Stock

Cramer wants to own FreshPet and prefers Pepsico over Dr Pepper Snapple.

Jim Cramer's 'Mad Money' Recap: Buy the Best and Leave the Rest

Jim Cramer's 'Mad Money' Recap: Buy the Best and Leave the Rest

Rarely does the market put the winning lottery ticket right in front of you, but today's winners were hiding in plain sight, Cramer says.

Biotechs and Drugmakers Expected to Seek More Mergers in 2015

Biotechs and Drugmakers Expected to Seek More Mergers in 2015

The perceived risk from macroeconomic issues — such as those in Europe — as well as changes in both interest rates and oil prices will make outright sales more attractive.

Dendreon's Asset Rummage Sale Completes the Circle of Life

Dendreon's Asset Rummage Sale Completes the Circle of Life

Valeant Pharmaceuticals is in a tentative deal to acquire the assets of Dendreon -- mostly its prostate-cancer vaccine Provenge and manufacturing facilities -- for $296 million in cash.

Advaxis: Legit Reasons to Take Another Look at Under-Appreciated Cancer Immunotherapy

Advaxis: Legit Reasons to Take Another Look at Under-Appreciated Cancer Immunotherapy

The hiring of a key Merck scientist and potential for combination cancer immunotherapy explain the recent rebound in Advaxis' stock price.

Trading Had an Odd Feel

There just wasn't a high level of commitment to the market.

Don't Think Like a Trader All the Time

Big money can be made by buying and holding for the outsize gains.

'Mad Money' Lightning Round: Constellation Brands the New King in Town

'Mad Money' Lightning Round: Constellation Brands the New King in Town

Cramer likes BioMarin over Juno Therapeutics, Cypress Semiconductor over Micron Technology and Take-Two Interactive over Zynga.

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

It's earnings, earnings and more earnings for Cramer next week.

On Hold for the ECB

Meanwhile, we have Netflix and IBM to entertain us.

10 Biggest Deals Involving Venture Capital-Backed Companies in 2014

10 Biggest Deals Involving Venture Capital-Backed Companies in 2014

Startups launching an IPO or were acquired by a bigger fish contributed to a 28% increase in the valuation of these so called exit deals by venture-backed companies in 2014.

This Market Is in Sad Shape

Potential for further downside is strong.

'Free the Webcast!' Investor Transparency Gains Momentum at 'JPM15' Healthcare Confab

'Free the Webcast!' Investor Transparency Gains Momentum at 'JPM15' Healthcare Confab

Following a week of awareness raising through phone calls, Twitter and a Loncar guest appearance on CNBC, the number of JPM breakout session webcasts has increased significantly.

Gilead Buying Vertex Among Bold Biotech Stock Predictions for 2015

Gilead Buying Vertex Among Bold Biotech Stock Predictions for 2015

The 2015 biotech stock predictions of TheStreet contributor David Sobek.

Biotech Investors' Guide and Preview to J.P. Morgan Healthcare Conference: Part 2

Biotech Investors' Guide and Preview to J.P. Morgan Healthcare Conference: Part 2

The much ballyhooed J.P. Morgan Healthcare Conference kicks off Monday in San Francisco. Here are capsule summaries of some of the expected story lines from presenting companies.

Juno Therapeutics To Present At The 33rd Annual J.P. Morgan Healthcare Conference

Juno Therapeutics To Present At The 33rd Annual J.P. Morgan Healthcare Conference

Juno Therapeutics, Inc. (NASDAQ:JUNO) today announced that it will webcast its presentation at the 33 rd Annual J.

Uncharted Waters

This is an odd market right now.

Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015

Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015

TheStreet's Adam Feuerstein lays down his predictions for the biotech industry for 2015.

After CAR-T: Getting Ahead of the Next Hot Trend in Cancer Stocks

After CAR-T: Getting Ahead of the Next Hot Trend in Cancer Stocks

Here's how investors can help fund the next cure for cancer: anti-CD47 antibody therapies.

Stick a Fork in 2014

We get a fresh start on Friday.

Juno Therapeutics (JUNO) Stock Sells Off Today Following Three Days of Gains

Juno Therapeutics (JUNO) Stock Sells Off Today Following Three Days of Gains

Shares of Juno Therapeutics (JUNO) fell in early afternoon trading Tuesday as the stock sold off following three days of significant gains.

Too Much Big Picture

Everyone's too busy talking about what might happen in 2015.

Juno Therapeutics (JUNO) Stock Touches New High

Juno Therapeutics (JUNO) Stock Touches New High

Shares of Juno Therapeutics (JUNO) soared to a new lifetime high of $56.50 on Monday after the biotech company filed an 8-K form.

Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens

Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens

Another crazy and profitable year in biotech investing was captured 140 characters at a time.